Unique Mechanism of Action

Centhaquine, a pharmacological resuscitative agent. Targets the vascular bottleneck in shock.

Case
Case

The New Paradigm in Hypovolemic shock Management

Key Improvement over Standard of Care

SEO

Contraindications:

Hypersensitivity to centhaquine or to any of the excipients

Case

Novel First-in-class Therapy

Increases cardiac output decreases vascular resistance

SEO
Unique Mechanism of Action
icon
Hypovolemic shock Management
icon
Key Improvement
icon
Contraindications
icon
Novel First-in-class Therapy
icon

Compared to the standard of care

Reduced Mortality
Reduced Mortality
Improve blood pressure
Improve blood pressure
Reduce blood lactate level
Reduce blood lactate level
Improved	ARDS
Improved ARDS

The New Paradigm in Hypovolemic Shock Management.

Lyfaquin® is indicated as a resuscitative agent for the treatment of patients with hypovolemic shock as an adjuvant to standard of care. Lyfaquin® uniquely stimulates α2B adrenergic receptors to increase venous blood return and cardiac output; and on α2A adrenergic receptors to decrease vascular resistance, thereby enhancing tissue blood perfusion. It is a key improvement over current therapy by complementing with standard of care.
Case

Lyfaquin® injection is a sterile preparation of 1.0 mg centhaquine citrate intended for intravenous use. The product is available as 10 mL amber tubular glass vial. It is soluble in sodium chloride Injection I.P. (0.9% w/v). The active ingredient centhaquine citrate is white crystalline powder with empirical formula C28H33N3O7 and molecular weight of 523.58. The chemical name of centhaquine citrate is, 2-[2-[4-(3-Methylphenyl)-1-piperazinyl]ethyl] quinoline citrate. Clinical study confirms that Lyfaquin® has a wide safety margin and the therapeutic dose is standardized as 0.01 mg / Kg body weight.

ABOUT US

Key Improvement over Standard of Care

Stimulates α2B
Stimulates α2B adrenergic receptors

Acts on α2B adrenergic receptors to produce venous constriction, increase venous return, increase cardiac output.

Stimulates a2A
Stimulates α2A adrenergic receptors

Acts on central α2A adrenergic receptors to reduce sympathetic drive, decrease systemic vascular resistance and improve tissue blood perfusion.

Reduced Mortality
Reduced Mortality

Significantly reduced mortality in hypovolemic shock

Improved ARDS
Improved ARDS

Improved ARDS and organ functions (MODS); Key divers of mortality

ventilators
Reduced average time on hospital stay

Reduced average time on ventilators, ICU, & hospital stay of seriously ill patients.

serious adverse
No serious adverse events

Well tolerated in clinical studies, no serious adverse events

Product Information

Therapeutic indication Hypovolemic Shock; as an adjuvant to standard of care
Dose 0.01 mg/kg body weight (Reconstitution in normal saline)
Intravenous infusion rate 100 mL in 1 hour
Dosing interval Minimum 4 hours (Time gap between two doses not less than 4 hours)
Total doses in a day 3 doses (Not more than 3 doses in a day/24 hours)
Maximum doses 6 doses (Not more than 6 doses in 2 days/48 hours)
Case

Important safety information

Contraindications:

Hypersensitivity to Centhaquine or to any of the excipients

Special warnings and precautions for use:

Lyfaquin® administration with precautions in hepatic failure, renal failure and decompensated heart failure patient as safety and efficacy of Lyfaquin® not established in the same cases

The safety and efficacy of Lyfaquin® is also not established in pregnancy, lactating women, pediatric and geriatric population.

Drugs interactions:

No drug-drug interaction or drug-food interaction observed